Good manufacturing practice production of CD34⁺ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia.

ABSTRACT: Allogeneic natural killer (NK) cell-based immunotherapy is a promising, well-tolerated adjuvant therapeutic approach for acute myeloid leukemia (AML). For reproducible NK cell immunotherapy, a homogenous, pure and scalable NK cell product is preferred. Therefore, we developed a good manufacturing practice (GMP)-compliant, cytokine-based ex vivo manufacturing process for generating NK cells from CD34⁺ hematopoietic stem and progenitor cells (HSPC). This manufacturing process combines amongst others IL15 and IL12 and the aryl hydrocarbon receptor antagonist StemRegenin-1 (SR1) to generate a consistent and active NK cell product that fits the requirements for NK cell immunotherapy well. The cell culture protocol was first optimized to generate NK cells with required expansion and d

SUBMITTER: de Jonge PKJD 

PROVIDER: S-EPMC10491545 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature